CoChat

Malvidin alleviates mitochondrial dysfunction and ROS accumulation through activating AMPK-α/UCP2 axis, thereby resisting inflammation and apoptosis in SAE mice

Open access
Zhao, Panpan, Li, Xiaomin, Yang, Qiankun, Lu, Yingzhi, Wang, Guanglu, Yang, Haitao, Dong, Jingquan, Zhang, Honggang · 2023 · Frontiers in Pharmacology

The DOI matches its Crossref record; 92 of the 93 references it cites were found in a registry or an index.

Abstract

This study aimed to explore the protective roles of malvidin in life-threatened sepsis-associated encephalopathy (SAE) and illustrate the underlying mechanism. SAE mice models were developed and treated with malvidin for subsequently protective effects evaluation. Malvidin restored neurobehavioral retardation, declined serum S100β and NSE levels, sustained cerebrum morphological structure, improved blood-brain barrier integrity with elevated tight junction proteins, and decreased evans blue leakage, and finally protect SAE mice from brain injury. Mechanistically, malvidin prevented cerebrum from mitochondrial dysfunction with enhanced JC-1 aggregates and ATP levels, and ROS accumulation with decreased lipid peroxidation and increased antioxidant enzymes. UCP2 protein levels were found to be decreased after LPS stimulation in the cerebrum and BV-2 cells, and malvidin recovered its levels in a ROS dependent manner. In vivo inhibition of UCP2 with genipin or in vitro interference with siRNA UCP2 both disrupted the mitochondrial membrane potential, decreased ATP levels and intensified DCF signals, being a key target for malvidin. Moreover, dorsomorphin block assays verified that malvidin upregulated UCP2 expression through phosphorylating AMPK in SAE models. Also, malvidin alleviated SAE progression through inhibition of ROS-dependent NLRP3 inflammasome activation mediated serum pro-inflammatory cytokines secretion and mitochondrial pathway mediated apoptosis with weakened apoptosis body formation and tunel positive signals, and decreased Bax, cytochrome C, caspase-3 and increased Bcl-2 protein levels. Overall, this study illustrated that malvidin targeted AMPK-α/UCP2 axis to restore LPS-induced mitochondrial dysfunction and alleviate ROS accumulation, which further inhibits NLRP3 inflammasome activation and mitochondrial apoptosis in a ROS dependent way, and ultimately protected SAE mice, providing a reference for the targeted development of SAE prophylactic approach.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2022.1038802

Cites

92 of 92 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Effects of malvidin on LPS-induced mice cerebrum injury. (A) Scores of neurological reflex indicators of auricular reflex, corneal reflex, turn-right reflex, tail-flick reflex and escape reflex (n = 12). (B–C) Serum S100β and NSE levels analysis using ELISA assays (n = 6). (D) Histopathological changes observations of cerebrum cortex using H&E staining (n = 6). The red arrows represent neuronal necrosis, green arrows represent glial cells, and yellow arrows represent capillary dilation. (E) Immunofluorescence observation of glial cells activation in the cerebrum. The green fluorescence signals are IBA1 positive cells, whereas the blue signals are cell nucleus. (F) Quantitative analysis of IBA1 positive cells percentage in cerebrum tissues (n = 3). (G–J) The mRNA relative expression levels analysis of tight junction proteins of ZO-1, claudin-5, occludin, and cadherin using RT-qPCR analysis (n = 6). (K) Quantitative analysis of evans blue leakage in cerebrum tissues under optical density values of 620 nm (n = 6). (L) Confocal microscope observation of evans blue leakage in the cerebrum cortex (white box). The red fluorescence signals are evans blue. Scale bar = 100 μm * represents comparison between LPS group and control group, whereas # indicates analysis among LPS group and malvidin pretreatment groups. # is p < 0.05, ## is p < 0.01, ***/### is p < 0.001, and ns is p > 0.05.
FIGURE 1 Effects of malvidin on LPS-induced mice cerebrum injury. (A) Scores of neurological reflex indicators of auricular reflex, corneal reflex, turn-right reflex, tail-flick reflex and escape reflex (n = 12). (B–C) Serum S100β and NSE levels analysis using ELISA assays (n = 6). (D) Histopathological changes observations of cerebrum cortex using H&E staining (n = 6). The red arrows represent neuronal necrosis, green arrows represent glial cells, and yellow arrows represent capillary dilation. (E) Immunofluorescence observation of glial cells activation in the cerebrum. The green fluorescence signals are IBA1 positive cells, whereas the blue signals are cell nucleus. (F) Quantitative analysis of IBA1 positive cells percentage in cerebrum tissues (n = 3). (G–J) The mRNA relative expression levels analysis of tight junction proteins of ZO-1, claudin-5, occludin, and cadherin using RT-qPCR analysis (n = 6). (K) Quantitative analysis of evans blue leakage in cerebrum tissues under optical density values of 620 nm (n = 6). (L) Confocal microscope observation of evans blue leakage in the cerebrum cortex (white box). The red fluorescence signals are evans blue. Scale bar = 100 μm * represents comparison between LPS group and control group, whereas # indicates analysis among LPS group and malvidin pretreatment groups. # is p < 0.05, ## is p < 0.01, ***/### is p < 0.001, and ns is p > 0.05.CC BY · PubMed Central
FIGURE 2 Roles of malvidin on LPS-induced mice cerebrum mitochondrial dysfunction and ROS accumulation. (A) JC-1 aggregates fluorescence intensity in the purified cerebrum mitochondrial was detected using mitochondrial membrane potential assay kit (n = 6). (B, C) ATP contents were measured both in the purified cerebrum mitochondrial and cerebrum tissue homogenates using ATP content assay kit (n = 6). (D) ROS levels were detected in the purified cerebrum mitochondrial using ROS assay kit with fluorescent probe H2DCFDA (n = 6). The MDA contents (E), SOD activities (F), GSH-Px activities (G), CAT activities (H) in cerebrum tissue homogenates were measured using biochemical kits (n = 6). * represents comparison between LPS group and control group, whereas # indicates analysis among LPS group and malvidin pretreatment groups. # is p < 0.05, **/## is p < 0.01, ***/### is p < 0.001, and ns is p > 0.05.
FIGURE 2 Roles of malvidin on LPS-induced mice cerebrum mitochondrial dysfunction and ROS accumulation. (A) JC-1 aggregates fluorescence intensity in the purified cerebrum mitochondrial was detected using mitochondrial membrane potential assay kit (n = 6). (B, C) ATP contents were measured both in the purified cerebrum mitochondrial and cerebrum tissue homogenates using ATP content assay kit (n = 6). (D) ROS levels were detected in the purified cerebrum mitochondrial using ROS assay kit with fluorescent probe H2DCFDA (n = 6). The MDA contents (E), SOD activities (F), GSH-Px activities (G), CAT activities (H) in cerebrum tissue homogenates were measured using biochemical kits (n = 6). * represents comparison between LPS group and control group, whereas # indicates analysis among LPS group and malvidin pretreatment groups. # is p < 0.05, **/## is p < 0.01, ***/### is p < 0.001, and ns is p > 0.05.CC BY · PubMed Central
FIGURE 3 Malvidin enhanced UCP2 protein expression in SAE mice cerebrum and LPS stimulated BV-2 cells. (A) UCP2 protein expression levels in the cerebrum tissues were detected using immunoblotting assays. GAPDH was used as an internal reference. (B) Gray ratio analysis of UCP2/GAPDH in (A) using ImageJ and excel software (n = 3). (C) Cell viability determination of BV-2 after stimulation with malvidin (10, 50, 100, 200, 500 μM) for 24 h using CCK8 assays. (D) Cell viability determination of BV-2 after stimulation with LPS (10, 50, 100, 500, 1000 ng/ml) for 24 h using CCK8 assays. (E) Cell viability determination of BV-2 after co-stimulation with 500 ng/ml LPS and malvidin (10, 50, 100, 200, 500 μM) for 24 h using CCK8 assays. (F) Immunoblotting assays detection of UCP2 protein expression levels in the BV-2 cells incubated with or without malvidin (50, 100, 200 μM) for 1 h followed by stimulation with 500 ng/ml LPS for 24 h. (G) Gray ratio analysis of UCP2/GAPDH in (F) using ImageJ and excel software (n = 3). * represents comparison between LPS group and control group, whereas # indicates analysis among LPS group and malvidin pretreatment groups. */# is p < 0.05, **/## is p < 0.01, ***/### is p < 0.001, and ns is p > 0.05.
FIGURE 3 Malvidin enhanced UCP2 protein expression in SAE mice cerebrum and LPS stimulated BV-2 cells. (A) UCP2 protein expression levels in the cerebrum tissues were detected using immunoblotting assays. GAPDH was used as an internal reference. (B) Gray ratio analysis of UCP2/GAPDH in (A) using ImageJ and excel software (n = 3). (C) Cell viability determination of BV-2 after stimulation with malvidin (10, 50, 100, 200, 500 μM) for 24 h using CCK8 assays. (D) Cell viability determination of BV-2 after stimulation with LPS (10, 50, 100, 500, 1000 ng/ml) for 24 h using CCK8 assays. (E) Cell viability determination of BV-2 after co-stimulation with 500 ng/ml LPS and malvidin (10, 50, 100, 200, 500 μM) for 24 h using CCK8 assays. (F) Immunoblotting assays detection of UCP2 protein expression levels in the BV-2 cells incubated with or without malvidin (50, 100, 200 μM) for 1 h followed by stimulation with 500 ng/ml LPS for 24 h. (G) Gray ratio analysis of UCP2/GAPDH in (F) using ImageJ and excel software (n = 3). * represents comparison between LPS group and control group, whereas # indicates analysis among LPS group and malvidin pretreatment groups. */# is p < 0.05, **/## is p < 0.01, ***/### is p < 0.001, and ns is p > 0.05.CC BY · PubMed Central
FIGURE 4 Inhibition of UCP2 on MMP changes, ATP production, and ROS release in malvidin pretreated LPS stimulated mice. Mice were gavaged with genipin prior to LPS injection. (A) UCP2 protein expression levels in the cerebrum tissues were detected using immunoblotting assays. GAPDH was used as an internal reference. (B) Gray ratio analysis of UCP2/GAPDH in (A) using ImageJ and excel software (n = 3). (C) JC-1 aggregates fluorescence intensity in the purified cerebrum mitochondrial was detected using mitochondrial membrane potential assay kit (n = 6). (D, E) ATP contents were measured both in the purified cerebrum mitochondrial and cerebrum tissue homogenates using ATP content assay kit (n = 6). (F) ROS levels were detected in the purified cerebrum mitochondrial using ROS assay kit with fluorescent probe H2DCFDA (n = 6). * represents comparison between LPS group and control group, # represents comparison between genipin group and control group, whereas & indicates analysis among LPS injection combined with malvidin treatment groups with or without genipin gavage groups. */& is p < 0.05, **/&& is p < 0.01, ***/###/&&& is p < 0.001, and ns is p > 0.05.
FIGURE 4 Inhibition of UCP2 on MMP changes, ATP production, and ROS release in malvidin pretreated LPS stimulated mice. Mice were gavaged with genipin prior to LPS injection. (A) UCP2 protein expression levels in the cerebrum tissues were detected using immunoblotting assays. GAPDH was used as an internal reference. (B) Gray ratio analysis of UCP2/GAPDH in (A) using ImageJ and excel software (n = 3). (C) JC-1 aggregates fluorescence intensity in the purified cerebrum mitochondrial was detected using mitochondrial membrane potential assay kit (n = 6). (D, E) ATP contents were measured both in the purified cerebrum mitochondrial and cerebrum tissue homogenates using ATP content assay kit (n = 6). (F) ROS levels were detected in the purified cerebrum mitochondrial using ROS assay kit with fluorescent probe H2DCFDA (n = 6). * represents comparison between LPS group and control group, # represents comparison between genipin group and control group, whereas & indicates analysis among LPS injection combined with malvidin treatment groups with or without genipin gavage groups. */& is p < 0.05, **/&& is p < 0.01, ***/###/&&& is p < 0.001, and ns is p > 0.05.CC BY · PubMed Central
FIGURE 5 Inhibition of UCP2 on MMP changes, ATP production, and ROS release in malvidin pretreated LPS stimulated BV-2 cells. BV-2 cells were transfected with si-UCP2 to inhibit UCP2 protein expression. (A) UCP2 protein expression levels in BV-2 cells were detected using immunoblotting assays. GAPDH was used as an internal reference. (B) Gray ratio analysis of UCP2/GAPDH in (A) using ImageJ and excel software (n = 3). (C,E) LSCM observation of JC-1 aggregates fluorescence signals (red) and monomers fluorescence signals (green) in BV-2 cells. The fluorescence density of JC-1 aggregates were analyzed using ImageJ software (n = 3). (D,F) ROS levels were detected in BV-2 cells using ROS assay kit with fluorescent probe H2DCFDA and analyzed using LSCM. The DCF positive signals were made statistical analysis (n = 3). (G) ATP production was measured in BV-2 cells using ATP content assay kit (n =3). Statistical analysis was conducted using one-way ANOVA followed by Tukey’s post hoc testing. * represents comparison between LPS group and control group, # represents comparison between si-UCP2 group and control group, whereas & indicates analysis among LPS injection combined with malvidin pretreatment groups with or without si-UCP2 interfering groups. & is p < 0.05, && is p < 0.01, ***/###/&&& is p < 0.001, and ns is p > 0.05.
FIGURE 5 Inhibition of UCP2 on MMP changes, ATP production, and ROS release in malvidin pretreated LPS stimulated BV-2 cells. BV-2 cells were transfected with si-UCP2 to inhibit UCP2 protein expression. (A) UCP2 protein expression levels in BV-2 cells were detected using immunoblotting assays. GAPDH was used as an internal reference. (B) Gray ratio analysis of UCP2/GAPDH in (A) using ImageJ and excel software (n = 3). (C,E) LSCM observation of JC-1 aggregates fluorescence signals (red) and monomers fluorescence signals (green) in BV-2 cells. The fluorescence density of JC-1 aggregates were analyzed using ImageJ software (n = 3). (D,F) ROS levels were detected in BV-2 cells using ROS assay kit with fluorescent probe H2DCFDA and analyzed using LSCM. The DCF positive signals were made statistical analysis (n = 3). (G) ATP production was measured in BV-2 cells using ATP content assay kit (n =3). Statistical analysis was conducted using one-way ANOVA followed by Tukey’s post hoc testing. * represents comparison between LPS group and control group, # represents comparison between si-UCP2 group and control group, whereas & indicates analysis among LPS injection combined with malvidin pretreatment groups with or without si-UCP2 interfering groups. & is p < 0.05, && is p < 0.01, ***/###/&&& is p < 0.001, and ns is p > 0.05.CC BY · PubMed Central
FIGURE 6 AMPK phosphorylation accelerates UCP2 protein expression in SAE models. (A) Phospho-AMPKα protein expression levels in the cerebrum tissues were detected using immunoblotting assays. GAPDH was used as an internal reference. (B) Gray ratio analysis of UCP2/GAPDH in (A) using ImageJ and excel software (n = 3). (C) Phospho-AMPKα and UCP2 protein expression levels in BV-2 cells pretreated with or without AMPK inhibitor dorsomorphin. (D) Gray ratio analysis of Phospho-AMPKα/GAPDH in (C) (n = 3). (E) Gray ratio analysis of UCP2/GAPDH in (C) (n = 3). Statistical analysis was conducted using one-way ANOVA followed by Tukey’s post hoc testing. * represents comparison between LPS group and control group, # represents comparison among malvidin groups and LPS group in (B) or between dorsomorphin group and control group in (D,E), whereas & indicates analysis among LPS injection combined with malvidin pretreatment groups with or without dorsomorphin pretreatment groups in (D, ). */#/& is p < 0.05, && is p < 0.01, ***/&&& is p < 0.001, and ns is p > 0.05.
FIGURE 6 AMPK phosphorylation accelerates UCP2 protein expression in SAE models. (A) Phospho-AMPKα protein expression levels in the cerebrum tissues were detected using immunoblotting assays. GAPDH was used as an internal reference. (B) Gray ratio analysis of UCP2/GAPDH in (A) using ImageJ and excel software (n = 3). (C) Phospho-AMPKα and UCP2 protein expression levels in BV-2 cells pretreated with or without AMPK inhibitor dorsomorphin. (D) Gray ratio analysis of Phospho-AMPKα/GAPDH in (C) (n = 3). (E) Gray ratio analysis of UCP2/GAPDH in (C) (n = 3). Statistical analysis was conducted using one-way ANOVA followed by Tukey’s post hoc testing. * represents comparison between LPS group and control group, # represents comparison among malvidin groups and LPS group in (B) or between dorsomorphin group and control group in (D,E), whereas & indicates analysis among LPS injection combined with malvidin pretreatment groups with or without dorsomorphin pretreatment groups in (D, ). */#/& is p < 0.05, && is p < 0.01, ***/&&& is p < 0.001, and ns is p > 0.05.CC BY · PubMed Central
FIGURE 7 Malvidin protects against LPS induced SAE mice cerebrum inflammation through inhibiting ROS-mediated NLRP3 inflammasome activation. (A) Pro-inflammatory cytokines IL-6 (A), TNF-α (B), IL-1β (C) secretion and LDH (D) release levels in the SAE mice serum. (E) The expression levels of NLRP3 inflammasome releated proteins of NLRP3, ASC and caspase-1 in the cerebrum tissues using immunoblotting assays. GAPDH was used as an internal reference. Gray ratio analysis of NLRP3/GAPDH (F), ASC/GAPDH (G) and caspase-1/GAPDH (H) in (E) using ImageJ and excel software (n = 3). (I) The expression levels of NLRP3 inflammasome releated proteins of NLRP3, ASC and caspase-1 in BV-2 cells lysates using immunoblotting assays. GAPDH was used as an internal reference. Gray ratio analysis of NLRP3/GAPDH (J), ASC/GAPDH (K), and caspase-1/GAPDH (L) in (I) using ImageJ and excel software (n = 3). Statistical analysis was conducted using one-way ANOVA followed by Tukey’s post hoc testing. * represents comparison between LPS group and control group, # represents comparison among malvidin groups and LPS group in (A–D, F–H) or between NAC group and control group in (J–L), whereas & indicates analysis among LPS injection combined with malvidin pretreatment groups with or without NAC pretreatment groups in (J–L). */# is p < 0.05, **/##/&& is p < 0.01, ***/###/&&& is p < 0.001, and ns is p > 0.05.
FIGURE 7 Malvidin protects against LPS induced SAE mice cerebrum inflammation through inhibiting ROS-mediated NLRP3 inflammasome activation. (A) Pro-inflammatory cytokines IL-6 (A), TNF-α (B), IL-1β (C) secretion and LDH (D) release levels in the SAE mice serum. (E) The expression levels of NLRP3 inflammasome releated proteins of NLRP3, ASC and caspase-1 in the cerebrum tissues using immunoblotting assays. GAPDH was used as an internal reference. Gray ratio analysis of NLRP3/GAPDH (F), ASC/GAPDH (G) and caspase-1/GAPDH (H) in (E) using ImageJ and excel software (n = 3). (I) The expression levels of NLRP3 inflammasome releated proteins of NLRP3, ASC and caspase-1 in BV-2 cells lysates using immunoblotting assays. GAPDH was used as an internal reference. Gray ratio analysis of NLRP3/GAPDH (J), ASC/GAPDH (K), and caspase-1/GAPDH (L) in (I) using ImageJ and excel software (n = 3). Statistical analysis was conducted using one-way ANOVA followed by Tukey’s post hoc testing. * represents comparison between LPS group and control group, # represents comparison among malvidin groups and LPS group in (A–D, F–H) or between NAC group and control group in (J–L), whereas & indicates analysis among LPS injection combined with malvidin pretreatment groups with or without NAC pretreatment groups in (J–L). */# is p < 0.05, **/##/&& is p < 0.01, ***/###/&&& is p < 0.001, and ns is p > 0.05.CC BY · PubMed Central
FIGURE 8 Malvidin protects against LPS induced mice cerebrum injury through inhibiting ROS-mediated apoptosis. (A) TEM observation of the microstructures of the nucleus of the cerebral cortex. (B) Tunel staining of apoptosis cells in the cerebrum. Scale bar = 100 µm. The tunnel positive cells were stained in red and nuclear is stained with DAPI (in blue). (C) The expression levels of apoptosis related proteins of Bax, Bcl-2, Cyto-C and caspase-3 in the cerebrum tissues using immunoblotting assays. GAPDH was used as an internal reference. Gray ratio analysis of Bax/GAPDH (D), Bcl-2/GAPDH (E), Cyto-C/GAPDH (F), caspase-3/GAPDH (G) in (C) using ImageJ and excel software (n = 3). (H) The expression levels of apoptosis related proteins of Bax and caspase-3 in the BV-2 cell lysates using immunoblotting assays. GAPDH was used as an internal reference. Gray ratio analysis of Bax/GAPDH (I), and caspase-3/GAPDH (J) in (H) using ImageJ and excel software (n = 3). * represents comparison between LPS group and control group, # represents comparison among LPS injection group and malvidin groups or between NAC group and control group, & indicates comparison among malvidin treatment followed by LPS injection groups with or without NAC pretreatment groups. */#/& is p < 0.05, **/## is p < 0.01, ***/###/&&& is p < 0.001, and ns is p > 0.05.
FIGURE 8 Malvidin protects against LPS induced mice cerebrum injury through inhibiting ROS-mediated apoptosis. (A) TEM observation of the microstructures of the nucleus of the cerebral cortex. (B) Tunel staining of apoptosis cells in the cerebrum. Scale bar = 100 µm. The tunnel positive cells were stained in red and nuclear is stained with DAPI (in blue). (C) The expression levels of apoptosis related proteins of Bax, Bcl-2, Cyto-C and caspase-3 in the cerebrum tissues using immunoblotting assays. GAPDH was used as an internal reference. Gray ratio analysis of Bax/GAPDH (D), Bcl-2/GAPDH (E), Cyto-C/GAPDH (F), caspase-3/GAPDH (G) in (C) using ImageJ and excel software (n = 3). (H) The expression levels of apoptosis related proteins of Bax and caspase-3 in the BV-2 cell lysates using immunoblotting assays. GAPDH was used as an internal reference. Gray ratio analysis of Bax/GAPDH (I), and caspase-3/GAPDH (J) in (H) using ImageJ and excel software (n = 3). * represents comparison between LPS group and control group, # represents comparison among LPS injection group and malvidin groups or between NAC group and control group, & indicates comparison among malvidin treatment followed by LPS injection groups with or without NAC pretreatment groups. */#/& is p < 0.05, **/## is p < 0.01, ***/###/&&& is p < 0.001, and ns is p > 0.05.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 46

Metadata

Authors
Zhao, P., Li, X., Yang, Q., Lu, Y., Wang, G., Yang, H., Dong, J., & Zhang, H.
Affiliations
  • The First People’s Hospital of Lianyungang (CN)
  • Jiangsu Ocean University (CN)
Corresponding author
Zhang, Honggang
Venue
Frontiers in Pharmacology
Published
2023-01-09
Volume
13
Pages
1038802-1038802
ISSN
1663-9812 (ISSN-L)
OpenAlex
W4313891039
Cited by
43
References
93
Citations by year
2026: 7 · 2025: 15 · 2024: 17 · 2023: 4
FWCI
3.83
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Government of Jiangsu Province
  • Priority Academic Program Development of Jiangsu Higher Education Institutions
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
  • Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
  • Health Sciences › Medicine › Pharmacology (medical) › Flavonoids in Medical Research
Keywords
malvidin, sepsis-associated encephalopathy, mitochondrial dysfunction, reactive oxygen species, NLRP3 inflammasome, neuroinflammation, mitochondrial apoptosis, blood-brain barrier integrity, lipopolysaccharide, genipin, flavonoids, neuroprotection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.